INT'L GROUP(SZ:000411)2021-04-23 16:00Financial Performance - The company's operating revenue for 2020 was ¥25,008,204,653.82, representing a 1.66% increase compared to ¥24,600,927,156.34 in 2019[6]. - The net profit attributable to shareholders for 2020 was ¥156,748,016.89, up 3.74% from ¥151,093,951.77 in 2019[6]. - The net profit after deducting non-recurring gains and losses was ¥148,309,091.67, a significant increase of 20.92% from ¥122,650,496.56 in 2019[6]. - The net cash flow from operating activities increased by 50.63% to ¥332,241,463.38 from ¥220,561,595.64 in 2019[6]. - Total assets at the end of 2020 were ¥11,250,269,584.65, a 4.46% increase from ¥10,769,459,422.20 at the end of 2019[18]. - The net assets attributable to shareholders increased by 9.42% to ¥1,660,032,536.25 from ¥1,517,114,589.43 in 2019[18]. - The company reported a basic earnings per share of ¥0.63, down 4.55% from ¥0.66 in 2019[6]. - The total comprehensive income for 2020 was ¥352,052,111.84, an increase of 3.64% from ¥339,675,455.37 in 2019[47]. - The company achieved a gross profit margin of 6.22% in 2020, with a slight decrease from the previous year[52]. - The company’s net profit for 2020 was ¥342,810,991.64, reflecting a 1.52% increase from ¥337,672,269.03 in 2019[47]. Dividend Distribution - The company plans to distribute a cash dividend of 0.65 CNY per 10 shares to all shareholders, based on a total of 248,939,935 shares[4]. - The total cash dividend proposed for 2020 is CNY 16,181,095.78, which corresponds to a dividend of CNY 0.65 per 10 shares[110]. - The cash dividend payout ratio for 2020 is 10.32% of the net profit attributable to the parent company, compared to 10.05% in 2019[108]. - As of December 31, 2020, the cumulative distributable profit available to shareholders was CNY 30,840,548.82, an increase from CNY 22,055,640.45 in 2019[106]. - The company did not propose any stock dividends or capital reserve transfers in the profit distribution plan for 2020[109]. - The total cash dividend amount for 2019 was CNY 15,185,336.04, which was 10.05% of the net profit for that year[108]. - The cash dividend for 2018 was significantly higher at CNY 26,968,492.98, with a payout ratio of 28.74%[108]. Business Operations - The company has maintained its main business focus on the wholesale of pharmaceuticals and medical devices, with no changes reported during the reporting period[16]. - The company plans to enhance its logistics capabilities and expand its pharmaceutical distribution network to improve market coverage and service efficiency[29][30]. - The company aims to leverage information technology and IoT to enhance its logistics management and service platform[29]. - The pharmaceutical wholesale sector accounted for 92.43% of total revenue, generating ¥23,114,570,382.01, while the pharmaceutical retail sector saw a significant growth of 30.95%, reaching ¥1,783,805,585.93[50]. - The company executed 410 government orders, transporting nearly 200 million pieces of protective materials during the pandemic[42]. - The company was recognized as a key pharmaceutical reserve unit in Zhejiang Province and received multiple honors for its contributions to pandemic response[42]. - The company is actively exploring new business models, including internet hospitals and pharmacy collaborations, to enhance its service capabilities[33]. - The company has seen a significant increase in equity assets, which rose by 243.40% due to the establishment of new joint ventures[28]. - The company achieved a 25% growth in its B2B e-commerce business through the "Internet + Pharmaceutical Distribution" platform[39]. Research and Development - Research and development expenses increased by 2.71% to ¥2,015,714.53 in 2020, compared to ¥1,962,519.06 in 2019[45]. - Investment in R&D increased by 30%, focusing on innovative drug development and new technologies[191]. Corporate Governance and Compliance - The company’s board of directors has confirmed the accuracy and completeness of the annual report, ensuring no false records or misleading statements[3]. - The company emphasizes strict compliance with drug quality management standards to mitigate risks related to product quality and safety[95]. - The company has established a robust corporate governance structure, ensuring independent operation of the board and management[113]. - The company will comply with legal and regulatory requirements in all related transactions, ensuring fair practices[114]. Market Position and Strategy - The company aims to become the largest pharmaceutical health service provider in Zhejiang Province, focusing on "internal growth, external expansion, integration, innovation, and ecosystem collaboration"[93]. - The company plans to enhance its competitive edge by integrating "business flow, capital flow, information flow, and logistics flow" in its supply chain strategy[93]. - The company is facing risks from healthcare reform policies and increasing market competition, which may impact its distribution business[94]. - The overall outlook for the company remains cautiously optimistic, with a focus on sustainable growth and profitability[182]. Employee and Management Changes - The total remuneration for directors, supervisors, and senior management during the reporting period amounted to 16.22 million CNY[196]. - The company employed a total of 2,710 staff, with 1,299 in sales, 204 in finance, and 81 in technical roles[197]. - The management team saw significant changes, with the appointment of 应徐颉 as the new General Manager on August 27, 2020, following the departure of 罗国良 and 财务总监 on July 22, 2020[181]. - The company has implemented a diverse training plan focusing on new employee onboarding, backup talent training, and middle management development[200]. Social Responsibility - The company organized a COVID-19 response team and supplied over 200 million pieces of protective materials, ensuring over 80% of the provincial government's emergency supply needs were met[147]. - The company donated a total of 900,000 RMB to support poverty alleviation projects in Jiangshan City, with an annual contribution of 300,000 RMB from 2018 to 2020[149]. - The company plans to continue its poverty alleviation efforts by focusing on sustainable income-generating industries such as traditional Chinese medicine planting and rural tourism development[154].